Avalo Therapeutics, Inc. SEC filings AVTX
Avalo Therapeutics, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to May 9, 2017. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, agreement ended). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 10, 2026 | — |
| DEF 14A | Proxy statement | Apr 10, 2026 | Apr 10, 2026 |
| DEFA14A | Additional proxy material | May 1, 2025 | — |
| DEF 14A | Proxy statement | May 1, 2025 | Jun 17, 2025 |
| DEFA14A | Additional proxy material | Jun 27, 2024 | — |
| DEF 14A | Proxy statement | Jun 27, 2024 | Aug 13, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 7, 2024 | Jun 7, 2024 |
| DEFA14A | Additional proxy material | Mar 28, 2024 | — |
| DEFA14A | Additional proxy material | Dec 7, 2023 | — |
| DEFA14A | Additional proxy material | Oct 19, 2023 | — |
| DEF 14A | Proxy statement | Oct 19, 2023 | Dec 5, 2023 |
| PRE 14A | Preliminary proxy statement | Oct 5, 2023 | Dec 5, 2023 |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 14, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2022 | Jun 14, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 15, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 18, 2020 |
| DEFA14A | Additional proxy material | Jun 19, 2019 | — |
| DEF 14A | Proxy statement | Jun 19, 2019 | Aug 7, 2019 |
| PRE 14A | Preliminary proxy statement | May 24, 2019 | Aug 7, 2019 |
| DEFA14A | Additional proxy material | Apr 18, 2018 | — |
| DEFA14A | Additional proxy material | Apr 18, 2018 | — |
| DEFA14A | Additional proxy material | Apr 5, 2018 | — |
| DEF 14A | Proxy statement | Apr 5, 2018 | May 15, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 13, 2018 | Dec 31, 2017 |
| PRE 14A | Preliminary proxy statement | May 12, 2017 | May 12, 2017 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534120
- Former names
- Cerecor Inc. (until Aug 18, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.